Gilead and arcus announce etrumadenant plus zimberelimab regimen significantly reduced the risk of death in third-line metastatic colorectal cancer

Foster city, calif. & hayward, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) and arcus biosciences, inc. (nyse: rcus) today announced new data from cohort b of arc-9, a phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual a2a/b adenosine receptor antagonist, plus anti-pd-1 monoclonal antibody zimberelimab, folfox chemotherapy and bevacizumab (ezfb) in third-line metastatic colorectal cancer (mcrc). these results will be presented today during an oral sessi.
RCUS Ratings Summary
RCUS Quant Ranking